A Novel B-Cell-Targeted Adjuvant APRIL Improves the Breadth and Persistence of Anti-SARS-CoV-2 Immunity
Vaccines · 13.11.2026 · 14 (11) · 976
DOI: 10.3390/vaccines14110976 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 13.11.2026. Verfasst von Hongye Wang und 11 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People’s Republic of China, National Natural Science Foundation of China, Yunnan Province Science and Technology Department.
Abstract (Originalsprache)
Background
A broad, robust, and long-lasting antibody response is essential for effective anti-SARS-CoV-2 immunity and the prevention of breakthrough infections. As a key member of the tumor necrosis factor superfamily, a proliferation-inducing ligand (APRIL) participates in multiple B cell fate processes, including B cell survival, class-switch recombination, and plasma cell (PC) differentiation, but its potential utility as a SARS-CoV-2 vaccine adjuvant remains largely unexplored.
Methods
Balb/c mice were immunized with recombinant XBB.1.5 S protein formulated with alum, with or without the addition of APRIL. Serum, bronchoalveolar lavage fluid (BALF), and fecal samples were collected for measuring antigen-specific IgG/IgA titers and antibody avidity by ELISA. Neutralization against Delta, BA.2.12.1, BF.7, XBB.1.5, and JN.1 was determined in HEK293-ACE2 cells, while cellular responses were assessed by flow cytometry and Enzyme-Linked Immunospot (ELISPOT). Gene expressions were quantified by RT-PCR.
Results
APRIL augmented the immunogenicity of XBB.1.5 S in a dose-dependent manner. It promoted the generation of both systemic and mucosal antibodies, broadened the binding breadth and avidity, and conferred superior neutralizing activity against multiple variants. During a 20-week post-immunization monitoring period, mice maintained effective antibody titers and retained the capacity to neutralize diverse variants. Mechanistically, APRIL was associated with upregulated AICDA and UNG mRNA expressions, accompanied by expansion of the B cell repertoire, differentiation into PCs and antigen-specific memory B cells, and maintenance of high-avidity long-lived PCs.
Conclusions
APRIL acts as an effective adjuvant that elicits broad-spectrum, long-lasting immunity against SARS-CoV-2 variants. It represents a promising immunostimulatory component for optimizing the performance of recombinant spike protein vaccines.
Förderung
- Ministry of Science and Technology of the People’s Republic of China
- National Natural Science Foundation of China
- Yunnan Province Science and Technology Department
- Yunnan Provincial Health Commission
Zitieren
APA
Wang, H., Guo, X., Jiang, X., Chen, C., Yang, H., Yang, Y., Zhu, X., Cheng, R., Li, B., Zhang, Z., Yao, Y., & Sun, M. (2026). A Novel B-Cell-Targeted Adjuvant APRIL Improves the Breadth and Persistence of Anti-SARS-CoV-2 Immunity. Vaccines, 14(11), 976. https://doi.org/10.3390/vaccines14110976
Vancouver
Wang H, Guo X, Jiang X, Chen C, Yang H, Yang Y, et al. A Novel B-Cell-Targeted Adjuvant APRIL Improves the Breadth and Persistence of Anti-SARS-CoV-2 Immunity. Vaccines. 2026;14(11):976. doi:10.3390/vaccines14110976
BibTeX
@article{Wang2026,
author = {Wang, Hongye and Guo, Xinwen and Jiang, Xinyu and Chen, Cheng and Yang, Huan and Yang, You and Zhu, Xiaoyong and Cheng, Rui and Li, Bingxiang and Zhang, Zijie and Yao, Yufeng and Sun, Ming},
title = {A Novel B-Cell-Targeted Adjuvant APRIL Improves the Breadth and Persistence of Anti-SARS-CoV-2 Immunity},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {11},
pages = {976},
doi = {10.3390/vaccines14110976}
}
EUVIMED